– USA, TX – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Bonnie H. Anderson to its Board of Directors. Ms. Anderson is the cofounder of Veracyte (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, where she serves as president and chief executive officer.
Ms. Anderson’s career spans nearly 30 years in the diagnostics and life sciences markets. She cofounded Veracyte in 2008, spearheaded its successful initial public offering in 2013 and has led its commercialization efforts to date. These include the introduction of Veracyte’s first product, the Afirma® Thyroid FNA Analysis, which is becoming a new standard of care in thyroid cancer diagnosis. The company also recently entered the pulmonology market with the launch of Percepta™ Bronchial Genomic Classifier to help reduce unnecessary invasive procedures in lung cancer diagnosis. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in various leadership roles at Beckman Coulter, a biomedical laboratory instruments company.
“We are excited to welcome an executive of Bonnie Anderson’s vision and talent to our Board of Directors,” said Dan Bradbury, Chairman of the Board of Castle Biosciences. “She has built a successful public company, and her strong financial and commercial expertise will be instrumental as we advance the clinical adoption and commercialization of Castle Biosciences’ diagnostic test services.”
Ms. Anderson is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences and holds a B.S. in Medical Technology from Indiana University of Pennsylvania. In 2012, the university honored her with a “Distinguished Alumni” award. In 2015, she was featured in Fast Company’s “100 Most Creative People in Business,” and in 2014 was named one of the “Bay Area’s Most Admired CEOs” by the San Francisco Business Times.
About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx™-UM), cutaneous melanoma (DecisionDx™-Melanoma) and esophageal cancer (DecisionDx™-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
